Answers are grounded in this paper and cite their sources.
Multicenter randomized trial evaluates lymph node metastasis and overall survival in esophageal cancer patients, highlighting therapy effectiveness.
Background Lymph node metastasis is one of the important prognostic factors for the overall survival(OS) of esophageal cancer patients. Neo-adjuvant therapy has a strong effect on the downstaging of tumor. But the therapeutic effects on the primary tumor and lymph node were not the same. The aim of this study was focus on metastasis status of lymph node and its influences on the OS for patients who have suffered from locally advanced esophageal cancer. Methods All the data we used in this study, was based on the multicenter randomized clinical trial(NCT03001596). Eligible patients staged as cT3–4aN0–1 M0 ESCC were randomly assigned (1: 1) to the neoadjuvant chemoradiotherapy group (nCRT) and neoadjuvant chemotherapy (nCT) group. The chemotherapy, based on paclitaxel and cisplatin, was administered to both groups, while concurrent radiotherapy was added for the nCRT group. Relationship between number of LND and perioperative, recurrence and survival outcomes were analyzed between the nCRT and nCT group. Results It showed a better pCR rate in the nCRT group, compared with nCT group (35.7% vs 3.8%, p < 0.01). But the three-year survival rate was comparable between nCRT group and nCT group (64.1% vs 54.9%, p = 0.27). When we compared the harvested lymph node number (LNN) between the two group, the positive LNN grew as the total number increased. It showed significant difference on the survival rate if we set 25 lymph nodes. It showed worse survival when the positive lymph node was found in MPR group of the patients. Positive LN indicated worse survival in both cohort at SD group. Conclusion Systemic lymph node dissection is associated with better survival and local disease control. Chemoradiotherapy showed a better therapeutic effect on the primary tumor site. Higher harvested LNN indicated a better OS. The positive lymph node rate was also lower in the nCRT group. But positive LN indicated worse survival in both group. Therefore, systemic lymphadenectomy should still be considered as an integrated part of surgery after Neo-adjuvant for ESCC.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: